Hanaa Ibrahim Rady
Cairo University, Egypt
Title: Magnesium sulphate as an adjuvant therapy in critically ill infants and children presenting with wheezy chest
Biography
Biography: Hanaa Ibrahim Rady
Abstract
Background: Wheezy chest remains one of the major causes for emergency department visits and admissions at Pediatric intensive care units (PICUs).
Objective: We aimed to determine the efficacy of magnesium sulphate (MgSO4) versus standard treatment in critically ill infants and children with wheezy chest.
Methodology: Randomized controlled trial comprised 81 patients suffering from wheezy chest divided into 3 groups. In addition to bronchodilators and systemic steroids, MgSO4 was given by inhalation in Group A, intravenously in Group B, and Group C received placebo. The improvement in our cases was determined by clinical respiratory score (CRS), ventilator setting and arterial blood gases (ABGs) before and after treatment.
Results: Median age was 11 months, mean weight 9.3kg and the median of SOFA score was one. After treatment: There was significant improvement of CRS in the three groups. In group A, there was significant reduction in ventilator rate (p=0.017) and improvement of arterial/inspired oxygen ratio (p=0.0056). In group B better mean arterial pH was noted (p=0.009).
Conclusion: Magnesium sulphate is a safe and beneficial adjuvant therapy in addition to standard treatment in critically ill infants and children with wheezy chest.